Table 1. Association of SPOCK1 expression with clinicopathological factors for 478 cases of IDC.
| Clinicopathological variables | SPOCK1 expression | Chi-square test | ||||
|---|---|---|---|---|---|---|
| Negative | Positive | Totala | χ2 | P | ||
| n (%) | n (%) | |||||
| Age (years) | -0.020 | 0.662 | ||||
| ≦50 | 197 (80.4) | 48 (19.6) | 245 | |||
| >50 | 191 (82.0) | 42 (18.0) | 233 | |||
| Pathological tumor size (cm) | 0.106 | 0.012* | ||||
| T1 | 125 (89.3) | 15 (10.7) | 140 | |||
| T2 | 215 (77.3) | 63 (22.7) | 278 | |||
| T3 and T4 | 47 (79.7) | 12 (20.3) | 59 | |||
| Pathological lymph node status | 0.027 | 0.558 | ||||
| Negative | 168 (82.4) | 36 (17.6) | 204 | |||
| Positive | 215 (80.2) | 53 (19.8) | 268 | |||
| Pathological tumor stage | 0.104 | 0.079 | ||||
| I | 78 (87.6) | 11 (12.4) | 89 | |||
| II | 183 (82.1) | 40 (17.9) | 223 | |||
| III | 122 (76.3) | 38 (23.8) | 160 | |||
| SBR grade | 0.105 | 0.013* | ||||
| I | 118 (83.7) | 23 (16.3) | 141 | |||
| II | 189 (84.4) | 35 (15.6) | 224 | |||
| III | 81 (71.7) | 32 (28.3) | 113 | |||
| Estrogen receptor | -0.143 | 0.002* | ||||
| Negative | 122 (73.5) | 44 (26.5) | 166 | |||
| Positive | 266 (85.3) | 46 (14.7) | 312 | |||
| Progesteron receptor | -0.051 | 0.261 | ||||
| Negative | 135 (78.5) | 37 (21.50) | 172 | |||
| Positive | 253 (82.7) | 53 (17.3) | 306 | |||
| HER2b | 0.058 | 0.205 | ||||
| Negative | 316 (82.3) | 68 (17.7) | 384 | |||
| Positive | 72 (76.6) | 22 (23.4) | 94 | |||
| Positivity for triple negativityc | 0.105 | 0.022* | ||||
| Negative | 335 (82.9) | 69 (17.1) | 404 | |||
| Positive | 53 (71.6) | 21 (28.4) | 74 | |||
| Basal-like phenotyped | 0.102 | 0.026* | ||||
| Negative | 377 (82.0) | 83 (18.0) | 460 | |||
| Positive | 11 (61.1) | 7 (38.9) | 18 | |||
| Adjuvant CT and/or HT | 0.068 | 0.152 | ||||
| Negative | 24 (92.3) | 2 (7.7) | 26 | |||
| Positive | 344 (81.1) | 80 (18.9) | 424 | |||
SBR grade, Scarff–Bloom–Richardson grade; CT, chemotherapy; HR, hormone therapy
*Significance level was set at P < 0.05
aNumbers do not always add up to 478 because of the lack of tumor excision and/or lymph node sampling in some cases.
bHER2-positive: HER2: 3+/3+ (IHC) or 2+/3+ (IHC) and positive on HER2 FISH test. HER2-negative: HER2: 0–1+/3+ (IHC) or HER2: 2+/3+, but negative on HER-2/neu FISH test. A commercially available dual-color FISH kit for simultaneous evaluation of HER-2/neu gene and chromosome 17 copy number was used according to the manufacturer instructions (PathVysion™ HER-2 DNA Probe Kit, Vysis, Inc., Downers Grove, IL, USA).
cPositivity for triple negativity: ER−, PR−, and HER2−.
dBasal-like phenotype: ER−, PR−, HER2−, and CK5/6+ (>10% tumor cells).